573 related articles for article (PubMed ID: 28534300)
21. Effect of particle size on oral absorption of carvedilol nanosuspensions: in vitro and in vivo evaluation.
Liu D; Pan H; He F; Wang X; Li J; Yang X; Pan W
Int J Nanomedicine; 2015; 10():6425-34. PubMed ID: 26508852
[TBL] [Abstract][Full Text] [Related]
22. Enhance the dissolution rate and oral bioavailability of pranlukast by preparing nanosuspensions with high-pressure homogenizing method.
Wang L; Hao Y; Liu N; Ma M; Yin Z; Zhang X
Drug Dev Ind Pharm; 2012 Nov; 38(11):1381-9. PubMed ID: 22300415
[TBL] [Abstract][Full Text] [Related]
23. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability.
Xia D; Quan P; Piao H; Piao H; Sun S; Yin Y; Cui F
Eur J Pharm Sci; 2010 Jul; 40(4):325-34. PubMed ID: 20417274
[TBL] [Abstract][Full Text] [Related]
24. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
Patel GV; Patel VB; Pathak A; Rajput SJ
Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
[TBL] [Abstract][Full Text] [Related]
25. Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation.
Jiang T; Han N; Zhao B; Xie Y; Wang S
Drug Dev Ind Pharm; 2012 Oct; 38(10):1230-9. PubMed ID: 22229827
[TBL] [Abstract][Full Text] [Related]
26. Preparation of apigenin nanocrystals using supercritical antisolvent process for dissolution and bioavailability enhancement.
Zhang J; Huang Y; Liu D; Gao Y; Qian S
Eur J Pharm Sci; 2013 Mar; 48(4-5):740-7. PubMed ID: 23305994
[TBL] [Abstract][Full Text] [Related]
27. Fabrication of carvedilol nanosuspensions through the anti-solvent precipitation-ultrasonication method for the improvement of dissolution rate and oral bioavailability.
Liu D; Xu H; Tian B; Yuan K; Pan H; Ma S; Yang X; Pan W
AAPS PharmSciTech; 2012 Mar; 13(1):295-304. PubMed ID: 22246736
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of solubility, antioxidant ability and bioavailability of taxifolin nanoparticles by liquid antisolvent precipitation technique.
Zu Y; Wu W; Zhao X; Li Y; Wang W; Zhong C; Zhang Y; Zhao X
Int J Pharm; 2014 Aug; 471(1-2):366-76. PubMed ID: 24882039
[TBL] [Abstract][Full Text] [Related]
29. Thermodynamic aspects of the preparation of amorphous solid dispersions of Naringenin with enhanced dissolution rate.
Jha DK; Shah DS; Amin PD
Int J Pharm; 2020 Jun; 583():119363. PubMed ID: 32334068
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.
Liu Y; Sun C; Hao Y; Jiang T; Zheng L; Wang S
J Pharm Pharm Sci; 2010; 13(4):589-606. PubMed ID: 21486533
[TBL] [Abstract][Full Text] [Related]
31. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
Nagaraj K; Narendar D; Kishan V
Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
[TBL] [Abstract][Full Text] [Related]
32. Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization.
Xu Y; Liu X; Lian R; Zheng S; Yin Z; Lu Y; Wu W
Int J Pharm; 2012 Nov; 438(1-2):287-95. PubMed ID: 22989976
[TBL] [Abstract][Full Text] [Related]
33. Influence of drug physicochemical properties on absorption of water insoluble drug nanosuspensions.
Li W; Quan P; Zhang Y; Cheng J; Liu J; Cun D; Xiang R; Fang L
Int J Pharm; 2014 Jan; 460(1-2):13-23. PubMed ID: 24184036
[TBL] [Abstract][Full Text] [Related]
34. Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability.
Rangaraj N; Pailla SR; Chowta P; Sampathi S
AAPS PharmSciTech; 2019 Oct; 20(8):326. PubMed ID: 31659558
[TBL] [Abstract][Full Text] [Related]
35. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.
Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N
Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401
[TBL] [Abstract][Full Text] [Related]
36. Quality by Design Approach for Developing Lipid-Based Nanoformulations of Gliclazide to Improve Oral Bioavailability and Anti-Diabetic Activity.
Patel P; Pailla SR; Rangaraj N; Cheruvu HS; Dodoala S; Sampathi S
AAPS PharmSciTech; 2019 Jan; 20(2):45. PubMed ID: 30617566
[TBL] [Abstract][Full Text] [Related]
37. Application of Central Composite Design in Optimization of Valsartan Nanosuspension to Enhance its Solubility and Stability.
Vuppalapati L; Cherukuri S; Neeli V; Yeragamreddy PR; Kesavan BR
Curr Drug Deliv; 2016; 13(1):143-57. PubMed ID: 26205900
[TBL] [Abstract][Full Text] [Related]
38. Preparation and Optimization of Amorphous Ursodeoxycholic Acid Nano-suspensions by Nanoprecipitation based on Acid-base Neutralization for Enhanced Dissolution.
Xie Y; Chen Z; Su R; Li Y; Qi J; Wu W; Lu Y
Curr Drug Deliv; 2017; 14(4):483-491. PubMed ID: 27593183
[TBL] [Abstract][Full Text] [Related]
39. Chitosan-coated diacerein nanosuspensions as a platform for enhancing bioavailability and lowering side effects: preparation, characterization, and ex vivo/in vivo evaluation.
Allam AN; Hamdallah SI; Abdallah OY
Int J Nanomedicine; 2017; 12():4733-4745. PubMed ID: 28740381
[TBL] [Abstract][Full Text] [Related]
40. Novel electrosprayed nanospherules for enhanced aqueous solubility and oral bioavailability of poorly water-soluble fenofibrate.
Yousaf AM; Mustapha O; Kim DW; Kim DS; Kim KS; Jin SG; Yong CS; Youn YS; Oh YK; Kim JO; Choi HG
Int J Nanomedicine; 2016; 11():213-21. PubMed ID: 26834471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
